Anti-Human MUC1 Recombinant Antibody (C595) (CAT#: TAB-429MZ)

Figure 1 Dose-tolerance studies for escalating single-dose administration of single or combination treatments for the first 3 weeks in nude mice without tumors.

Dose-tolerance relationship in mice by single MAb C595.

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).

Figure 2 Dose-tolerance studies for escalating single-dose administration of single or combination treatments for the first 3 weeks in nude mice without tumors.

Dose-tolerance relationship in mice by combination test [MAb C595 (5 mg/kg)+DTX (3–10 mg/kg)].

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).

Figure 3 Dose-tolerance studies for escalating single-dose administration of single or combination treatments for the first 3 weeks in nude mice without tumors.

Dose-tolerance relationship in mice by combination control [MAb IgG3 control (5 mg/kg)+DTX (3–10 mg/kg)].

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).

Figure 4 Cumulative ascites volume, tumor weight and CA125 levels at the end of experiments after single MAb C595 and DTX treatment in OVCAR-3 animal model.

Cumulative volumes of ascites collected from each animal from initiation of therapy [MAb C595 (H and L), MAb IgG3, DTX (H and L) are shown. The obvious difference was seen between DTX(H)-treated group and others-treated group (P<0.05).

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).

Figure 5 Cumulative ascites volume, tumor weight and CA125 levels at the end of experiments after single MAb C595 and DTX treatment in OVCAR-3 animal model.

Tumor weights (mg) at the end of experiments after single MAb C595, MAb IgG3, DTX or vehicle treatments with different doses. The tumor weigh was obviously lower in MAb-treated and DTX-treated groups compared to MAbIgG3-treated and HPMC-treated control groups (P<0.05).

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).

Figure 6 Cumulative ascites volume, tumor weight and CA125 levels at the end of experiments after single MAb C595 and DTX treatment in OVCAR-3 animal model.

Effect of single MAb C595, MAb IgG3, DTX or vehicle on suppressing the increase in the tumor marker CA125 (CA125 Ku/L) in the ascites fluid (peritoneal wash) at the end of experiments. The level of CA125 was obviously lower in MAb C595 (H)-treated and DTX-treated groups compared to MAbIgG3-treated and HPMC-treated control groups (P<0.05).

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).

Figure 7 Representative images of histological changes, MUC1 and CD31 expression at the end of experiments after combination and control treatments.

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).

Figure 8 Representative images of Ki-67, TUNEL, Caspase-3 (Active) and PARP-1 (Cleaved 85) at the end of experiments after combination and control treatments.

Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).